Understanding right heart fat in PAH and how it affects function
Official title: Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension
Funded at Vanderbilt University Medical Center · NIH-11385327 · Data updated 2026-11-12
This NIH grant studies why the right side of the heart accumulates fat in people with pulmonary arterial hypertension and how that affects exercise and heart failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 25, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $716,036 |
| NIH project number | 5R01HL155278-05 |
| Project ID | NIH-11385327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with pulmonary arterial hypertension, especially those with evidence of right ventricular lipid accumulation or insulin resistance.
✕Less likely to help
Patients without PAH or without right ventricular lipid changes may not benefit from this research.
What this research studies
If funded, researchers at Vanderbilt will use imaging and tissue samples to understand how fat builds up in the right ventricle in PAH and how this relates to heart muscle function and exercise capacity. The project builds on findings that link lipid metabolism problems to PAH and RV lipid accumulation, and it aims to identify mechanisms that could be targeted with therapies like metabolic drugs. By combining human data with analyses from muscle and heart tissue, the study seeks to connect changes in lipid processing to worse heart performance. The ultimate goal is to pave the way for treatments that improve heart function and quality of life for PAH patients.
Why it matters
Potential benefit: If successful, the work could lead to new approaches to treat right heart failure in PAH and improve exercise tolerance.
How similar studies have gone: Previous studies have linked lipid metabolism abnormalities to PAH and RV dysfunction, with early data suggesting possible modulation by metabolic drugs.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Brittain, Evan L — Vanderbilt University Medical Center
- Study coordinator: Brittain, Evan L
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.